(108 days)
Not Found
No
The description focuses on automatic calculations based on user-specified coordinates and fiducial markers, which is a deterministic process, not indicative of AI/ML. There is no mention of learning, training data, or complex pattern recognition beyond geometric calculations.
No.
The device is a software application that assists in planning interventional procedures by calculating the location and depth for a biopsy needle; it does not directly treat or diagnose a disease.
No
The device is a software application that assists in planning MRI-guided interventional procedures by calculating the location and depth for biopsy needle insertion. It does not perform a diagnosis itself, but rather aids in the guidance of a procedure that might be used as part of a diagnostic process.
Yes
The device is described as a "software application" and a "software program" that assists users in planning procedures using information from MR images. The description focuses entirely on the software's functionality and calculations, with no mention of accompanying hardware components included with the device itself. The performance studies listed are all software verification and validation tests.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body (like blood, urine, tissue) to detect diseases, conditions, or infections. They are used outside the body.
- Device Function: The QuantX Breast MRI Biopsy Guidance Plugin is a software application that assists in planning in vivo (within the body) procedures. It uses medical images (MRI) to guide a physical intervention (biopsy needle insertion).
- No Sample Analysis: The device does not analyze biological samples. It processes image data to provide guidance for a procedure performed directly on the patient.
Therefore, while it's a medical device used in a diagnostic context (assisting in obtaining a biopsy for diagnosis), its function is not that of an In Vitro Diagnostic. It's a medical imaging software used for procedural planning.
N/A
Intended Use / Indications for Use
The QuantX Breast MRI Biopsy Guidance Plugin is a software application that assists users of the QuantX software device in planning MRI guided interventional procedures.
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
The QuantX Breast MRI Biopsy Guidance Plugin assists users in planning MRI quided interventional procedures. Using information from MR images regarding the coordinates of a user-specified region of interest and fiducial coordinates, the software provides an automatic calculation of the location and depth of the targeted region of interest, such as a lesion or suspected lesion. Its primary goal is to identify where and how deep a biopsy needle should be inserted into an imaged breast in order to strike a targeted lesion or region of interest, as chosen by a trained medical professional. The QuantX Breast MRI Biopsy Guidance Plugin may be used in either the SE or Advanced version of QuantX, a software program used for the display and analysis of medical images.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
MRI
Anatomical Site
Breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Trained medical professional.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical tests included:
- Verification of proper activation of biopsy guidance mode and interface display;
- Verification of proper creation of needle block images;
- Verification of proper loading of image series to be used in biopsy guidance;
- Verification of complete and correct selection of grid type variables;
- Verification of complete and correct needle type variables;
- Verification of correct fiducial marker image-space coordinates;
- Verification of correct size of grid image overlay and location;
- Verification of correct lesion marker overlay display and image-space coordinates;
- Verification of proper display of selected breast, grid cell, and block hole;
- Verification of proper display of needle block image and needle depth:
- Verification of correct patient orientation indicators:
- Verification of lesion depth calculation by comparison to predicate;
- Verification of correct needle block hole by comparison to predicate;
- Verification of correct grid cell by comparison to predicate;
- Verification of quidance worksheet output;
- Validation testing demonstrates that the device conforms to user needs and intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue, with the words "U.S. FOOD & DRUG" stacked on top of the word "ADMINISTRATION".
November 8, 2019
Qlarity Imaging, LLC % Mr. Robert Tomek Chief Technology Officer 222 W Merchandise Mart Plaza Suite 1230 CHICAGO IL 60654
Re: K191959
Trade/Device Name: QuantX Breast MRI Biopsy Guidance Plugin Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: Class II Product Code: LLZ Dated: July 19, 2019 Received: October 16, 2019
Dear Mr. Tomek:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
2
Indications for Use
510(k) Number (if known) K191959
Device Name
QuantX Breast MRI Biopsy Guidance Module
Indications for Use (Describe)
The QuantX Breast MRI Biopsy Guidance Plugin is a software application that assists users of the QuantX software device in planning MRI guided interventional procedures.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Premarket Notification 510(k) Summary
1.1 Submitter
| Manufacturer: | Qlarity Imaging, LLC |
|---|---|
| Address: | 222 W Merchandise Mart Plaza #1230 |
| Chicago, IL 60654 | |
| Contact Person: | Robert Tomek |
| Contact Person Title: | Chief Technology Officer |
| Telephone: | 872.529.2239 |
| Email: | rtomek@qlarityimaging.com |
| Date Prepared: | August 28, 2019 |
1.2 Device Information
510(k) Submission type: Traditional
Device Trade Name: QuantX Breast MRI Biopsy Guidance Plugin
Device Common Name: Image Processing System
510(k) Submitter: Qlarity Imaging, LLC
Classification Regulation: 21 CFR 892.2050
Classification Regulation Name: Radiology
Regulatory Class: Class II
Classification Product Code: LLZ
1.3 Leqally Marketed Predicate Device
The legally marketed predicate device is:
| Device Name | Manufacturer
Name | 510(k)
References | Product
Code | Classification |
|-------------|----------------------------|----------------------|-----------------|----------------|
| DynaCAD | MRI Devices
Corporation | K041286 | LLZ | Class II |
1.4 Device Description
The QuantX Breast MRI Biopsy Guidance Plugin assists users in planning MRI quided interventional procedures. Using information from MR images regarding the coordinates of a user-specified region of interest and fiducial coordinates, the software provides an automatic calculation of the location and depth of the targeted region of interest, such as a lesion or suspected lesion.
4
lts primary goal is to identify where and how deep a biopsy needle should be inserted into an imaged breast in order to strike a targeted lesion or region of interest, as chosen by a trained medical professional.
The QuantX Breast MRI Biopsy Guidance Plugin may be used in either the SE or Advanced version of QuantX, a software program used for the display and analysis of medical images.
1.5 Indications for Use
The QuantX Breast MRI Biopsy Guidance Plugin is a software application that assists users of the QuantX software device in planning MRI quided interventional procedures.
1.6 Technological Characteristics
The QuantX Breast MRI Biopsy Guidance Plugin has the following same technological characteristics as the predicate device.
- User-initiated selection of target breast (left or right) and direction of ● approach (medial or lateral).
- Customized image display depending on side and direction of approach. ●
- User-initiated placement of fiducial marker and biopsy grid. ●
- User-initiated selection of needle size and block combination within the biopsy panel.
- Display of image overlay for fiducial marker and biopsy grid. ●
- Display of image overlay for target region of interest location and sample ● needle trajectory.
- Calculation and display of coordinates and depth to reqion of interest. .
The following technological differences exist between the subject and predicate device; these differences do not affect the safety and effectiveness of the device when used as labeled:
- Subject device is a plugin that can be used in either the SE or Advanced versions of QuantX, a software program that analyzes patient breast images, and is designed to aid radiologists in the characterization of lesions as part of high-risk screening or diagnostic work-up. The predicate device is an image processing system designed to assist in the visualization, analysis, and reporting of magnetic resonance imaging (MRI) studies. Additionally, the predicate device assists users in planning MRI guided interventional procedures.
These differences do not affect the safety and effectiveness of the device when used as labeled.
5
1.7 NON-CLINICAL PERFORMANCE DATA TESTING AND REVIEWS - as required by 807.92(b)(1)
The QuantX Breast MRI Biopsv Guidance Plugin has been successfully tested for its software requirements and features. Nonclinical tests included:
- Verification of proper activation of biopsy guidance mode and interface . display;
- Verification of proper creation of needle block images; ●
- Verification of proper loading of image series to be used in biopsy guidance; ●
- Verification of complete and correct selection of grid type variables; ●
- Verification of complete and correct needle type variables; ●
- Verification of correct fiducial marker image-space coordinates;
- Verification of correct size of grid image overlay and location;
- Verification of correct lesion marker overlay display and image-space ● coordinates;
- Verification of proper display of selected breast, grid cell, and block hole;
- Verification of proper display of needle block image and needle depth: ●
- . Verification of correct patient orientation indicators:
- Verification of lesion depth calculation by comparison to predicate; ●
- . Verification of correct needle block hole by comparison to predicate;
- Verification of correct grid cell by comparison to predicate; ●
- Verification of quidance worksheet output; ●
- Validation testing demonstrates that the device conforms to user needs and ● intended use.
Based on these tests, we conclude that the subject device is safe and effective and substantially equivalent to the predicate device.
1.8 Conclusion
Based on the information supplied in this 510(k), we conclude that the subject device is safe, effective, and substantially equivalent to the predicate device.